A Look at Achieve Life Sciences's Valuation After Rare FDA Priority Voucher for Nicotine Vaping Therapy

Achieve Life Sciences (ACHV) just made headlines after receiving a rare FDA Commissioner's National Priority Voucher for cytisinicline, its investigational treatment aimed at nicotine vaping cessation. This move significantly shortens the expected FDA review timeline.

See our latest analysis for Achieve Life Sciences.

News of the expedited review for cytisinicline has ignited momentum. Achieve Life Sciences' share price soared by over 36% in just one day, with a 42% gain over the past month. Even after this surge, its one-year total shareholder return remains down 17%. However, the strong three-year total shareholder return of 65% suggests that optimism around the company’s pipeline and regulatory progress could be building again.

If breakthroughs in biotech spark your interest, now’s a good moment to discover See the full list for free.

With the stock rallying after the news, the key question for investors is whether Achieve Life Sciences remains undervalued at current levels or if expectations for future growth are already reflected in the price.

Price-to-Book of 5.2x: Is it justified?

Achieve Life Sciences trades at a price-to-book ratio of 5.2x, noticeably lower than the peer average of 13x. At the last close of $4.20, the stock appears comparatively undervalued against its direct competitors in terms of this metric.

The price-to-book ratio shows how much investors are paying for each dollar of the company's net assets. For a biotech with limited historical revenue, this multiple highlights market expectations around future breakthroughs, not just the current balance sheet.

While Achieve’s multiple is appealing compared to peers, especially in a sector where most companies trade on pipeline potential, it is important to recognize that compared to the biotech industry average of 2.5x, it looks expensive on an industry-wide basis. The valuation could change as the narrative around future profitability develops or as new data emerges about its lead asset.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Book of 5.2x (ABOUT RIGHT)

However, setbacks in regulatory approval or weaker-than-expected trial outcomes remain key risks. These factors could challenge the current optimism around Achieve Life Sciences.

Find out about the key risks to this Achieve Life Sciences narrative.

Another View: SWS DCF Model Signals Deep Undervaluation

While the price-to-book ratio frames Achieve Life Sciences as potentially expensive relative to the broader biotech industry, our DCF model offers a very different perspective. According to this approach, the stock is trading at almost 98% below our estimate of fair value. Could the market be underestimating Achieve’s long-term potential, or is there something the DCF model is missing?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Achieve Life Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Achieve Life Sciences Narrative

If you'd rather dig into the details yourself or want to challenge these conclusions, you can start building your own perspective in just minutes. Do it your way.

A great starting point for your Achieve Life Sciences research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.

Looking for More Investment Ideas?

If you want an edge in the market, don't stop at just one stock. Use these powerful tools and seize the opportunities others might overlook:

• Boost your returns by targeting undervalued companies with solid fundamentals using these 878 undervalued stocks based on cash flows.
• Jump into the future of healthcare innovation by scanning these 33 healthcare AI stocks, uncovering groundbreaking advances in AI-driven medicine and diagnostics.
• Capture steady income and growth by reviewing these 18 dividend stocks with yields > 3%, offering high yields and financial resilience in any market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com